연구성과로 돌아가기

2024 연구자 정보 (272 / 1079)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lam, Lisa H.
(Lam, LH) ⓘ 		Genentech Inc, Prod Dev Oncol, South San Francisco, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Lee, Jungbin
(Lee, J) ⓘ 		Pohang Univ Sci & Technol, Dept Mech Engn, Pohang, Gyeongsangbuk D, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] Fluoroquinolone-based fluorescence microscopic live imaging of conjunctival goblet cells for diagnosing dry eye disease ⓘ SCIE ⓘ 8.7 OPHTHALMOLOGY ⓘ ⓘ
Mattos, Cesar Torres
(Mattos, CT) ⓘ 		Chemotherapy SI Dnipropetrovsk MA MOHU, Dnipro, Ukraine ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
O'Shaughnessy, Joyce
(O'Shaughnessy, J) ⓘ 		Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Oliveira, Mafalda
(Oliveira, M) ⓘ 		Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain
Vall dHebron Inst Oncol, Breast Canc Grp, Barcelona, Spain ⓘ 		I-1695-2015
Oliveira, Mafalda ⓘ 		0000-0001-9152-8799
Oliveira, Mafalda ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Reilly, Sarah-Jayne
(Reilly, SJ) ⓘ 		Roche Prod Ltd, Welwyn Garden City, England ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Rodriguez, Jorge Luis Martinez
(Rodriguez, JLM) ⓘ 		Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Rojas, Beatriz
(Rojas, B) ⓘ 		Ctr Integral Oncol Clara Campal, Oncol Serv, Madrid, Spain ⓘ KIE-8235-2024
Rojas, Beatriz ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Sablin, Marie-Paule
(Sablin, MP) ⓘ 		Inst Curie, Dept Drug Dev & Innovat D3i, Paris, France ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Saji, Shigehira
(Saji, S) ⓘ 		Fukushima Med Univ, Dept Med Oncol, Fukushima, Japan ⓘ MFH-6808-2025
Saji, Shigehira ⓘ 		0000-0002-6732-8030
Saji, Shigehira ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Savas, Peter
(Savas, P) ⓘ 		Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Australia
Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia ⓘ
ⓘ 		0000-0001-5999-428X
Savas, Peter ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Schmid, Peter
(Schmid, P) ⓘ 		제1저자 교신저자 Queen Mary Univ London, Barts Canc Inst, London, England
Barts Canc Inst, Ctr Expt Canc Med, Old Anat Bldg, London EC1M 6BQ, England ⓘ 		LDG-1690-2024
SCHMID, PETER J ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Shah, Kalpit
(Shah, K) ⓘ 		Genentech Inc, Oncol Biomarker Dev, South San Francisco, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
Shin, Min Chul
(Shin, MC) ⓘ 		Kyungpook Natl Univ, Sch Mech Engn, 80 Daehak Ro, Daegu 41566, South Korea
Kyungpook Natl Univ, Sch Mech Engn, Daegu 41566, South Korea ⓘ 		AAU-6206-2021
Shin, Min ⓘ
ⓘ 		[JCR상위 8.7] Cell chip device for real-time monitoring of drug release from drug-laden microparticles
[JCR상위 18.1] Microneedle patch casting using a micromachined carbon master for enhanced drug delivery ⓘ 		SCIE ⓘ 8.7 BIOCHEMICAL RESEARCH METHODS;CHEMISTRY, ANALYTICAL;CHEMISTRY, MULTIDISCIPLINARY;INSTRUMENTS & INSTRUMENTATION;NANOSCIENCE & NANOTECHNOLOGY
MULTIDISCIPLINARY SCIENCES ⓘ 		gyuman.kim@knu.ac.kr;
bhkim@ssu.ac.kr;gyuman.kim@knu.ac.kr; ⓘ
Turner, Nicholas C.
(Turner, NC) ⓘ 		Royal Marsden NHS Fdn Trust, London, England
Breast Canc Now Res Ctr, London, England ⓘ
ⓘ 		0000-0001-8937-0873
Turner, Nicholas ⓘ 		[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ SCIE ⓘ 8.7 ONCOLOGY ⓘ p.schmid@qmul.ac.uk; ⓘ
페이지 이동: